Amniotics Past Earnings Performance
Past criteria checks 0/6
Amniotics's earnings have been declining at an average annual rate of -15.9%, while the Biotechs industry saw earnings declining at 1.4% annually. Revenues have been growing at an average rate of 169.3% per year.
Key information
-15.9%
Earnings growth rate
45.1%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 169.3% |
| Return on equity | -198.7% |
| Net Margin | n/a |
| Next Earnings Update | 24 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Amniotics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -31 | 32 | 0 |
| 30 Sep 23 | 0 | -35 | 34 | 0 |
| 30 Jun 23 | 0 | -45 | 42 | 0 |
| 31 Mar 23 | 0 | -49 | 45 | 0 |
| 31 Dec 22 | 0 | -48 | 45 | 0 |
| 30 Sep 22 | 0 | -51 | 48 | 0 |
| 30 Jun 22 | 0 | -45 | 43 | 0 |
| 31 Mar 22 | 0 | -52 | 50 | 0 |
| 31 Dec 21 | 0 | -54 | 51 | 0 |
| 30 Sep 21 | 0 | -54 | 53 | 0 |
| 30 Jun 21 | 0 | -50 | 48 | 0 |
| 31 Mar 21 | 0 | -38 | 40 | 0 |
| 31 Dec 20 | 0 | -31 | 29 | 0 |
| 31 Dec 19 | 0 | -10 | 10 | 0 |
| 31 Dec 18 | 0 | -7 | 7 | 0 |
Quality Earnings: AMNI is currently unprofitable.
Growing Profit Margin: AMNI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMNI is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare AMNI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMNI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: AMNI has a negative Return on Equity (-198.66%), as it is currently unprofitable.